Denver, CONCT07088926Now EnrollingIRB Ready

Bronchiectasis With Pseudomonas Aeruginosa Colonization Clinical Trial in Denver, CO

Access cutting-edge bronchiectasis with pseudomonas aeruginosa colonization treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access bronchiectasis with pseudomonas aeruginosa colonization specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bronchiectasis with pseudomonas aeruginosa colonization treatment provided free

Apply for This Denver Location

Check if you qualify for this bronchiectasis with pseudomonas aeruginosa colonization clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Bronchiectasis With Pseudomonas Aeruginosa Colonization Study in Denver

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participant must be ≥ 12 years of age at the time of signing the informed consent/assent
Weight ≥ 35 kg
Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility.
Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics
Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization
Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening.
Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening
Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study.
Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol

Exclusion Criteria

Primary lung diagnosis other than bronchiectasis
Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Participants currently receiving treatment for active TB or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy
Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment
Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed
Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment
AIDS or Advanced human immunodeficiency virus disease (CD4 count of \< 200 cells/mm3)
History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration
Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening
Chronic immunosuppressive therapy (including prednisolone \> 5 mg or equivalent) newly initiated within the last 3 months
Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study
Participants with CF on CFTR modulator therapies which are newly initiated within the previous 3 months prior to screening
Female participants who are pregnant, lactating, or WOCBP and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT07088926) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bronchiectasis With Pseudomonas Aeruginosa Colonization Treatment Options in Denver, CO

If you're searching for bronchiectasis with pseudomonas aeruginosa colonization treatment options in Denver, CO, this clinical trial (NCT07088926) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bronchiectasis with pseudomonas aeruginosa colonization specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bronchiectasis with pseudomonas aeruginosa colonization clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Denver, CO

See all ankylosing spondylitis clinical trials recruiting in Denver — not just this study.

Browse Ankylosing Spondylitis Trials in Denver →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsSleep Apnea TrialsBronchiectasis TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO